AstraZeneca’s Chief Government mentioned on Tuesday that the outcomes of a examine exhibiting its COVID-19 vaccine had little impact in opposition to gentle illness have been regarding however pressured that it ought to work in opposition to extreme types.
“It’s in fact a priority,” Pascal Soriot mentioned of the examine at a World Well being Group assembly.
“Having mentioned that the sufferers within the examine have been sufferers with gentle illness and we consider the vaccine ought to nonetheless defend in opposition to extreme illness.”
AstraZeneca is a serious provider to a WHO-backed vaccine-sharing scheme known as COVAX.
(Apart from the headline, this story has not been edited by NDTV workers and is revealed from a syndicated feed.)